Cristin-resultat-ID: 1395592
Sist endret: 4. januar 2017, 13:09
NVI-rapporteringsår: 2016
Resultat
Vitenskapelig artikkel
2016

Achievement of remission and low disease activity definitions in patients with rheumatoid arthritis in clinical practice: Results from the Nor-Dmard study

Bidragsytere:
  • Till Uhlig
  • Elisabeth Lie
  • Vibeke Norvang
  • Åse Lexberg
  • Erik Rødevand
  • Frode Krøll
  • mfl.

Tidsskrift

Journal of Rheumatology
ISSN 0315-162X
e-ISSN 1499-2752
NVI-nivå 1

Om resultatet

Vitenskapelig artikkel
Publiseringsår: 2016
Publisert online: 2016
Trykket: 2016
Volum: 43
Hefte: 4
Sider: 717 - 724

Importkilder

Scopus-ID: 2-s2.0-84982149350

Beskrivelse Beskrivelse

Tittel

Achievement of remission and low disease activity definitions in patients with rheumatoid arthritis in clinical practice: Results from the Nor-Dmard study

Sammendrag

Objective. To examine the frequency of 6 definitions for remission and 4 definitions for low disease activity (LDA) after starting a disease-modifying antirheumatic drug (DMARD) in patients with rheumatoid arthritis (RA) in clinical practice, and to study whether predictors for achieving remission after 6 months are similar for these definitions. Methods. Remission and LDA were calculated according to the 28-joint Disease Activity Score (DAS28), the Clinical Disease Activity Index (CDAI), the Simplified Disease Activity Index (SDAI), the Routine Assessment of Patient Index Data (RAPID3), and both the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) Boolean remission definitions 3 and 6 months after 4992 DMARD prescriptions for patients enrolled in the NOR-DMARD, a 5-center Norwegian register. Prediction of remission after 6 months was also studied. Results. After 3 months, remission rates varied between definitions from 8.7% to 22.5% and for LDA from 35.5% to 42.7%, and increased slightly until 6 months of followup. DAS28 and RAPID3 gave the highest and ACR/EULAR, SDAI, and CDAI the lowest proportions for remission. Positive predictors for remission after 6 months were similar across the definitions and included lower age, male sex, short disease duration, high level of education, current nonsmoking, nonerosive disease, treatment with a biological DMARD, being DMARD-naive, good physical function, little fatigue, and LDA. Conclusion. In daily clinical practice, the DAS28 and RAPID3 definitions identified remission about twice as often as the ACR/EULAR Boolean, SDAI, and CDAI. Predictors of remission were similar across remission definitions. These findings provide additional evidence to follow treatment recommendations and treat RA early with a DMARD.

Bidragsytere

Aktiv cristin-person

Tillmann Uhlig

Bidragsyterens navn vises på dette resultatet som Till Uhlig
  • Tilknyttet:
    Forfatter
    ved Ortopedisk - Ullevål ved Universitetet i Oslo
  • Tilknyttet:
    Forfatter
    ved Nasjonal kompetansetjeneste for revmatologisk rehabilitering (NKRR) ved Diakonhjemmet sykehus

Elisabeth Lie

  • Tilknyttet:
    Forfatter
    ved Revmatologisk avdeling ved Diakonhjemmet sykehus

Vibeke Norvang

  • Tilknyttet:
    Forfatter
    ved Revmatologisk avdeling ved Diakonhjemmet sykehus

Åse Lexberg

  • Tilknyttet:
    Forfatter
    ved Drammen sykehus ved Vestre Viken HF

Erik Rødevand

  • Tilknyttet:
    Forfatter
    ved Klinikk for ortopedi, revmatologi og hudsykdommer ved St. Olavs Hospital HF
1 - 5 av 9 | Neste | Siste »